Well, it seams that this company has confirmed that it is a “Johnny one note”
Once again, I have to say since Manuso has taken charge; all they have to show for the tenure are big bounces and perks paid and the same drug they started with in the first place.
You know it, I know it and the street knows it.
We have all of the sounds of an empty drum from Manuso, with no new results.
Unless and until they launch a new compound, nothing new in over a decade, we will have nuttin!
Let us hope that they can launch a new compound soon.
When FDA denied on AML, I figured EU would go the same way. Now I am surprised that approval didn't even spike volume. I could understand old hands selling into strength after the pre-decision run-up and keeping the price stagnant, but volume is acting as though nothing happened.
At least we now have the J&J machine pushing this stuff in the EU. Orphan designation and a $5 mil milestone won't hurt either. Maybe a change in earnings will start share price appreciation.